Evolution of saliva and serum components in patients with oral candidosis topically treated with Ketoconazole and Nystatin.
The present study involves the analysis of some saliva components (SC) and serum components in patients with oral candidosis topically treated with Ketoconazole 2% (K) or Nystatin 100,000 IU (N). Twenty-four male and female patients, age range 39-82 years, were included in the study. A double-blind study was undertaken in which the patients were divided into 2 treatment groups. These groups were compared with a control group (CG) of 16 healthy patients, both male and female, age-matched with the treated groups. The parameters evaluated were oral mucous membrane lesion index (MLI), CFU of Candida, saliva flow rate, protein-bound Fe (Fe-prot), Fe-prot binding capacity (Fe-prot cap), IgAs, peroxidase activity (PA), hypothiocyanite and thiocyanite. The values of Candida CFU and MLI were significantly reduced in patients treated with K and N. The pre-treatment values of SC as compared to the CG revealed a reduction in Fe-prot and Fe-prot cap. These parameters reach values similar to control towards the end of the treatment. The PA was significantly higher in candidosis patients and fell to control values with treatment. The other SC and serum components did not exhibit significant differences with the CG. Patients with oral candidosis treated locally exhibit not only an improvement in clinical manifestations but also a return to control values of altered SC.
Cornejo
L S
LS
Departments of Biology, Clinical Stomatology, Introduction to Biochemistry and Biophysics, and Biochemistry and Biophysics, Faculty of Dentistry, National University of Córdoba, Córdoba, Argentina.
López de Blanc
S
S
Femopase
F
F
Azcurra
A
A
Calamari
S
S
Battellino
L J
LJ
Dorronsoro de Cattoni
S T
ST
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000935:Antifungal Agents / Q000008:administration & dosage*; D002180:Candidiasis, Oral / Q000097:blood / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007501:Iron / Q000378:metabolism; D007654:Ketoconazole / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009061:Mouth Mucosa / Q000473:pathology; D009761:Nystatin / Q000008:administration & dosage*; D009195:Peroxidase / Q000378:metabolism; D011485:Protein Binding; D012463:Saliva / Q000737:chemistry / Q000378:metabolism; D013861:Thiocyanates / Q000032:analysis; D016896:Treatment Outcome
D000935:Antifungal Agents; D013861:Thiocyanates; D009761:Nystatin; C014607:hypothiocyanite ion; D007501:Iron; D009195:Peroxidase; D007654:Ketoconazole